Indication
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic agent

Medicine details

Medicine name:
tofacitinib (Xeljanz)
SMC ID:
SMC2122
Pharmaceutical company
Pfizer Ltd
BNF chapter
Gastro-intestinal system
Submission type
Full submission
Status
Advice due date:
11 February 2019
SMC meeting date:
08 January 2019
Patient group submission deadline:
03 December 2018